Open AccessThis article is
- freely available
The Role of Monoclonal Antibodies in the Management of Leukemia
Department of Leukemia, the University of Texas MD Anderson Cancer Center, Houston, TX 77005, USA
Department of Internal Medicine, Hematology Oncology section, Oklahoma University Health Sciences Center, 700 N.E. 13th Street, Oklahoma City, OK 74103, USA
* Author to whom correspondence should be addressed.
Received: 20 September 2010; Accepted: 18 October 2010 / Published: 18 October 2010
Abstract: This article will review the monoclonal antibodies more commonly used in leukemias. In the last three decades, scientists have made considerable progress understanding the structure and the functions of various surface antigens, such as CD20, CD33. The introduction of rituximab, an anti CD20 monoclonal antibody, had a great impact in the treatment of lymphoproliferative disorders. Gemtuzumab, an anti CD 33 conjugated monoclonal antibody has activity in acute mylegenous leukemia (AML). As this field is undergoing a rapid growth, the years will see an increasing use of monoclonal antibodies in hematological malignancies.
Keywords: monoclonal Abs; leukemia; CLL; AML; ALL
Citations to this Article
Cite This Article
MDPI and ACS Style
Al-Ameri, A.; Cherry, M.; Al-Kali, A.; Ferrajoli, A. The Role of Monoclonal Antibodies in the Management of Leukemia. Pharmaceuticals 2010, 3, 3258-3274.
Al-Ameri A, Cherry M, Al-Kali A, Ferrajoli A. The Role of Monoclonal Antibodies in the Management of Leukemia. Pharmaceuticals. 2010; 3(10):3258-3274.
Al-Ameri, Ali; Cherry, Mohamad; Al-Kali, Aref; Ferrajoli, Alessandra. 2010. "The Role of Monoclonal Antibodies in the Management of Leukemia." Pharmaceuticals 3, no. 10: 3258-3274.